Author’s response to reviews

Title: The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report

Authors:

CATERINA DE BENEDITTIS (caterina.de@unibo.it)
CRISTINA PAPAYANNIDIS (cristina.papayannidis@gmail.com)
CLAUDIA VENTURI (ventclod85@katamil.com)
MARIA CHIARA ABBENANTE (maria.abbenante@gmail.com)
STEFANIA PAOLINI (stefania.paolini@unibo.it)
SARAH PARISI (sarah.parisi@alice.it)
CHIARA SARTOR (chiara.sartor1988@gmail.com)
MICHELE CAVO (michele.cavo@unibo.it)
GIOVANNI MARTINELLI (giovannimartinelli2@gmail.com)
SIMONA SOVERINI (simona.soverini@unibo.it)

Version: 3 Date: 06 Jul 2017

Author’s response to reviews:

Dear Dr Rice and Dr Solera,

please find herewith enclosed the revised version of the manuscript entitled "The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report" by De Benedittis et al, for consideration for publication in BMC Cancer.

We thank the reviewers for their thoughtful evaluation of our manuscript. We agree with all their comments and we have revised our manuscript accordingly.
A point-by-point description of such changes in response to editor’s comments is detailed below.

Editor Comments:

Comment #1: As suggested by Editor we have removed the Additional file2_CAREchecklist and Cover letter from the file inventory.

Comment #2: As suggested by Editor we have now removed the ambiguous statement present in the ‘Ethics approval and consent to participate’ subsection. We have added the consent to publish.

Comment #3: As suggested by Editor we have indicated that none specific funding were involved in the design of the study and collection, analysis, and interpretation of data and in writing this manuscript.

Comment #4: we have indicated with StP (Stefania Paolini) and SaP (Sarah Parisi)

Comment #5: we have now upload a single final and clear version of the manuscript.

After 16 months from first submission, we now hope that our manuscript will undergo a rapid revision and will soon be accepted for publication in BMC Cancer.

Thank you in advance for your assistance

Kind regards

Caterina De Benedittis, on behalf of all co-authors